01:22:12 EST Sun 16 Feb 2025
Enter Symbol
or Name
USA
CA



Login ID:
Password:
Save
Sernova Corp
Symbol SVA
Shares Issued 303,612,686
Close 2024-08-09 C$ 0.245
Market Cap C$ 74,385,108
Recent Sedar Documents

Sernova appoints Rigby as CEO

2024-08-12 15:24 ET - News Release

Mr. James Parsons reports

SERNOVA CORP. ANNOUNCES APPOINTMENT OF NEW CHIEF EXECUTIVE OFFICER

Jonathan Rigby has joined Sernova Corp. as its new chief executive officer.

James Parsons, on behalf of the board of directors of Sernova, stated: "The board believes that Sernova is now positioned to achieve its strategic milestones under Jonathan's leadership. Jonathan brings a track record of success raising equity capital for biotech companies. Jonathan has led multiple biotech companies through listings onto Nasdaq and the achievement of key operational and clinical developments, leading to strategic acquisitions that have generated significant value for shareholders."

On his appointment, Mr. Rigby commented: "As a type 1 diabetic myself, I am honoured to serve the company and its shareholders as Sernova's new CEO. I am passionate about Sernova's mission and determined to lead the company to realize its full potential. I have financed and grown multiple companies through to exits and my goal is clear; I will work tirelessly with the team to do the same for Sernova and its shareholders."

Mr. Rigby has held several CEO roles and currently serves on the board of directors of cancer therapy company, Oncolytics Biotech Inc., and IM Therapeutics, working in the diabetes field. He was formerly a board member of Xeris Pharmaceuticals, which developed and commercialized a product to treat type 1 diabetes severe hypoglycemia. Mr. Rigby holds a degree in biological sciences from the University of Sheffield, U.K., and has a master of business administration degree from the University of Portsmouth, U.K.

The board thanks Cynthia Pussinen, the company's former CEO, for her dedication and service to the company and wishes her the very best in her future endeavours.

About Sernova Corp.

Sernova is a clinical-stage biotechnology company that is developing therapeutic cell technologies that are implanted in patients inside its Cell Pouch system for chronic diseases, including a continuing phase 1/2a trial in insulin-dependent diabetes and plans to enter the clinic in thyroid disease, and blood disorders that include hemophilia A.

We seek Safe Harbor.

© 2025 Canjex Publishing Ltd. All rights reserved.